Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT04493853
Title	Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency (CAPItello-281)
Acronym	CAPItello-281
Recruitment	Active, not recruiting
Gender	male
Phase	Phase III
Variant Requirements	Yes
Sponsors	AstraZeneca
Indications	prostate adenocarcinoma
Therapies	Abiraterone + Capivasertib Abiraterone
Age Groups:	adult \| senior
Covered Countries	USA \| TUR \| SVK \| POL \| NLD \| ISR \| GBR \| FRA \| ESP \| DEU \| CZE \| CAN \| BRA \| BGR \| BEL \| AUT \| AUS \| ARG